Loading viewer...
investor_presentation
Format: PDF investor_presentation
Lenzing AG presented nine-month 2018 results showing revenue of EUR 1.6 billion with EBITDA of EUR 290.6 million in a challenging market. The company maintained a strong balance sheet with 59.5% adjusted equity ratio and progressed its sCore TEN specialty strategy, achieving 44.1% specialty product rate while expanding lyocell production capacity in Austria.
investor_presentation
35 Pages
investor_presentation
24 Pages
PTC India Limited
Teva Pharmaceutical Industries Investor Presentation — January 2022
investor_presentationinvestor_presentation
15 Pages
Teva Pharmaceutical Industries